ArticleThe Journal of experimental medicine1989
Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis.
Article in The Journal of experimental medicine, 1989. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 247 citations in OpenAlex.
- Antimonial therapy induces circulating proinflammatory cytokines in patients with cutaneous leishmaniasis.Infection and immunity · 2002Trial
- Leishmaniasis in Patients With Inflammatory Bowel Disease: A National Multicenter Study of GETECCU.United European gastroenterology journal · 2025Observational
- Genetic Iron Overload Hampers Development of Cutaneous Leishmaniasis in Mice.International journal of molecular sciences · 2023Article
- Host SUMOylation Pathway Negatively Regulates Protective Immune Responses and PromotesFrontiers in cellular and infection microbiology · 2022Article
- Susceptibility to Intracellular Infections: Contributions of TNF to Immune Defense.Frontiers in microbiology · 2020Review
- Cutaneous leishmaniasis associated with TNF-α blockers: a case report.European journal of hospital pharmacy : science and practice · 2019Article
- Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.Frontiers in immunology · 2019Review
- Cutaneous, mucocutaneous and visceral leishmaniasis in Sweden from 1996-2016: a retrospective study of clinical characteristics, treatments and outcomes.BMC infectious diseases · 2018Observational
- Association of a functional TNF variant with Plasmodium falciparum parasitaemia in a congolese population.Genes and immunity · 2017Article
- The meteorology of cytokine storms, and the clinical usefulness of this knowledge.Seminars in immunopathology · 2017Review
- Enhanced survival of Leishmania major in neutrophil granulocytes in the presence of apoptotic cells.PloS one · 2017Article
- Article
- TNF-Mediated Restriction of Arginase 1 Expression in Myeloid Cells Triggers Type 2 NO Synthase Activity at the Site of Infection.Cell reports · 2016Article
- Fatal Leishmaniasis in the Absence of TNF Despite a Strong Th1 Response.Frontiers in microbiology · 2015Article
- Article
- Article
- 2,3,7,8-tetrachlorodibenzo-p-dioxin slows the progression of experimental cutaneous Leishmaniasis in susceptible BALB/c and SCID mice.PloS one · 2013Article
- 17-AAG kills intracellular Leishmania amazonensis while reducing inflammatory responses in infected macrophages.PloS one · 2012Article
- Protective immunity and vaccination against cutaneous leishmaniasis.Frontiers in immunology · 2012Article
- Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection.Vaccine · 2009Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The ability of mice to resist infection with L. major correlated directly with the capacity of their LNC to produce TNF in response to in vitro parasite challenge. Blocking TNF in vivo by passively administering anti-TNF antibodies exacerbated the course of L. major infection, resulting in substantially larger cutaneous lesions and elevated numbers of parasites within those lesions. In addition, treatment of infected mice with exogenous rHuTNF afforded host protection as evidenced by smaller lesion size and decreased parasite counts. Taken together, these results suggest a central role for TNF in resistance to L. major.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.